Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.6696 -0.0239 (-3.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
How Worrisome Is Ocugen's Latest Bad News?
Investors don't need to be too concerned about the FDA's clinical hold on a Covaxin study-- for now. 
Via The Motley Fool
Exposures COVID-19 Product Safety
How Are The Shorts Feeling About Ocugen Inc?
What happened: Ocugen Inc's (NASDAQ:OCGN) short interest has fallen 14% since the last report. The company recently reported that it has 46 million shares sold short, which is... 
Via Benzinga
RNG Stock Alert: The COO News That RingCentral Investors Hanging Up Their Shares Today
RingCentral (RNG) stock isn't doing so hot on Thursday with heavy trading after the company announced a change in leadership. 
Via InvestorPlace
Investor Fears About Covaxin Have Ocugen Shares on Sale
OCGN stock at this point is either an inexpensive Covid-19 vaccine stock or an over-priced investigational gene therapy stock — or both. 
Via InvestorPlace
Exposures COVID-19
RENN Stock Alert: Why “Facebook of China” Renren Is Plunging Today
Renren (RENN) stock is falling hard on Thursday following an update on a $300 million court case against the Facebook of China. 
Via InvestorPlace
Topics Lawsuit
Exposures Financial Legal
OCGN Stock Pops on Key FDA News. Here’s What to Know.
Ocugen is slipping today even after promising news breaks related to its gene therapy program, OCU400. Where is OCGN stock heading? 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
2 Big Stock Bets That Are Insiders Are Buying Now
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
Via InvestorPlace
Ocugen Investors Are Betting On a Horse Than Can’t Win the Race
Don't go bottom-fishing with OCGN stock even if it's at an enticing support level 
Via InvestorPlace
Ocugen Looks Risky as Markets Tire Of Speculative Vaccine Plays
The window of opportunity is closing for also-ran vaccine makers, which is why OCGN has become a very volatile stock in the vaccine space. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Very Well May Have Bottomed Out Here
I don’t know if InvestorPlace’s Larry Ramer is still short, but if he is, he’s made a few bucks with OCGN stock down in the past month. 
Via InvestorPlace
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
20 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results... 
Via Benzinga
56 Biggest Movers From Friday
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on... 
Via Benzinga
OCGN Stock Alert: The FDA News Sending Ocugen Plummeting Today
Shares of OCGN stock are under pressure after the FDA halted the approval process of Covaxin, a major setback for Ocugen. 
Via InvestorPlace
Exposures Product Safety
48 Stocks Moving In Friday's Mid-Day Session
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded... 
Via Benzinga
Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold
The FDA has issued a clinical hold on Ocugen Inc's (NASDAQ: OCGN) Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate,... 
Via Benzinga
Exposures COVID-19 Product Safety
25 Stocks Moving in Friday's Pre-Market Session
Gainers iSpecimen Inc. (NASDAQ: ISPC) rose 56.9% to $16.00 in pre-market trading. The company recently announced it has been contracted to support new advanced research on COVID-... 
Via Benzinga
3 Small-Cap COVID Stocks With Huge Upside
Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics. 
Via The Motley Fool
Exposures COVID-19
Think Twice Before You Roll the Dice on Ocugen Stock
OCGN stock may spike once again on positive news, but investors' best best is to steer clear of it at this point in time. 
Via InvestorPlace
Exposures COVID-19
Ocugen-Partnered Bharat Biotech's COVID-19 Shot Shows 50% Effectiveness In Small Study In India
Bharat Biotech's vaccine was found to be 50% effective at preventing symptomatic COVID-19 in a high-risk population during the second wave of infections in India this year,... 
Via Benzinga
Exposures COVID-19
Better Buy: Ocugen or Novavax?
Will either of these hopeful vaccine makers continue to thrash the market? 
Via The Motley Fool
Exposures COVID-19
Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen
Both vaccine makers still have big hurdles to jump. 
Via The Motley Fool
Exposures COVID-19
Ocugen Stock: Bull vs. Bear
There's more to this potential coronavirus vaccine stock than what happens in the next 12 months. 
Via The Motley Fool
Exposures COVID-19
Why Ocugen Shot 8% Higher on Friday
There was some highly encouraging news about coronavirus vaccines, but not the one the company is associated with. 
Via The Motley Fool
Exposures COVID-19
The Slide in Ocugen Could Be a Slide to a Homerun
Ocugen has potential for its gene therapy treatment for eye diseases, but OCGN stock movement has been all about Covaxin. 
Via InvestorPlace
Why This Meme Stock Isn't Worth the Trouble
This biotech is targeting a lucrative market, but it may be too late for the company. 
Via The Motley Fool
3 Biotech Stocks That Have More Than Tripled so far This Year
But can they keep up the momentum? 
Via The Motley Fool
2 More Stocks Set to 2x… 5x… 10x in 2022
Finding 10x stocks is possible; it's simply a matter of knowing what patterns to look for. Here are a couple of strong contenders. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Things About Ocugen That Smart Investors Know
Revenue may not be right around the corner. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.